Table 2.
Central TMA | Agreement (%) | Kappa (95 % CI) | |||
---|---|---|---|---|---|
Clinical ER status | ER-negative, n (%) | ER-positive, n (%) | |||
All cases, n = 1085 | |||||
ER-negative, n (%) | 259 (90) | 42 (5) | 94 | 0.84 (0.80–0.87) | |
ER-positive, n (%) | 28 (10) | 756 (95) | |||
Concordant, n = 985 | |||||
ER-negative, n (%) | 217 (96) | 32 (4) | 96 | 0.89 (0.86–0.92) | |
ER-positive, n (%) | 8 (4) | 728 (96) | |||
Discordant, n = 100 | |||||
ER-negative, n (%) | 42 (68) | 10 (26) | 70 | 0.39 (0.22–0.57) | |
ER-positive, n (%) | 20 (32) | 28 (74) | |||
Clinical PR status | PR-negative, n (%) | PR-positive, n (%) | |||
All cases, n = 1085 | |||||
PR-negative, n (%) | 305 (80) | 41 (6) | 89 | 0.76 (0.72–0.80) | |
PR-positive, n (%) | 75 (20) | 664 (94) | |||
Concordant, n = 916 | |||||
PR-negative, n (%) | 246 (91) | 27 (4) | 95 | 0.87 (0.83–0.90) | |
PR-positive, n (%) | 23 (9) | 620 (96) | |||
Discordant, n = 169 | |||||
PR-negative, n (%) | 59 (53) | 14 (24) | 61 | 0.25 (0.12–0.38) | |
PR-positive, n (%) | 52 (47) | 44 (76) | |||
Clinical HER2 status | Negative | Equivocal | Positive | ||
All cases, n = 1085 | |||||
Negative, n (%) | 864 (93) | 16 (80) | 28 (21) | 88 | 0.57 (0.51–0.63) |
Equivocal, n (%) | 49 (5) | 2 (10) | 13 (10) | ||
Positive, n (%) | 17 (2) | 2 (10) | 94 (70) | ||
Concordant, n = 889 | |||||
Negative, n (%) | 768 (99) | 7 (88) | 22 (21) | 96 | 0.78 (0.72–0.84) |
Equivocal, n (%) | 4 (0) | 0 (0) | 1 (1) | ||
Positive, n (%) | 5 (1) | 1 (12) | 81 (78) | ||
Discordant, n = 196 | |||||
Negative, n (%) | 96 (63) | 9 (75) | 6 (19) | 57 | 0.16 (0.07–0.28) |
Equivocal, n (%) | 45 (29) | 2 (17) | 12 (39) | ||
Positive, n (%) | 12 (8) | 1 (8) | 13 (42) |
Abbreviations: ER estrogen receptor, HER2 human epidermal growth factor receptor 2, PR progesterone receptor, TMA tissue microarray
Concordant cases are those with the same biomarker status across all cores for a given case, while discordant cases are those with discordant biomarker status between any two cores for a given case